PhagoMed Biopharma is a biotechnology company developing phage therapies to replace ineffective antibiotics that is headquartered in Vienna, Austria and was founded in 2017 by Alexander Belcredi and Burkhard Wippermann.
PM398 is a phage therapy designed to destroy multi-drug resistant methicillin-resistant Staphylococcus aureus (MRSA).
On August 28, 2018 PhagoMed Biopharma completed a seed funding round with €4M in funding from from undisclosed investors.
Documentaries, videos and podcasts
PhagoMed - Virtual Tour (aws Phoenix video in English)
February 13, 2019
PhagoMed Biopharma uses technology to find alternative to antibiotics
January 8, 2019
PhagoMed PM398 in action
November 13, 2018
- BiotechnologyBiotechnology can refer to the application of science and technology to living organisms or the use of living organisms, their parts, products or models thereof to solve a problem, produce knowledge or produce goods and services. Biotechnology may involve the alteration of living or non-living materials.